Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Circulatory system drugs >  Antiarrhythmics Drugs >  Procainamide hydrochloride

Procainamide hydrochloride

Basic information Safety Supplier Related

Procainamide hydrochloride Basic information

Product Name:
Procainamide hydrochloride
Synonyms:
  • 2-[[(4-aminophenyl)-oxomethyl]amino]ethyl-diethylammonium
  • 4-AMINO-N-[2'-(DIETHYLAMINO)ETHYL]BENZAMIDE HCL
  • 4-AMINO-N-(2-DIETHYLAMINOETHYL)BENZAMIDE HYDROCHLORIDE
  • 4-AMINOBENZOIC ACID 2-DIETHYLAMINOETHYLAMIDE HYDROCHLORIDE
  • PROCAINE AMIDE HYDROCHLORIDE
  • PROCAINAMIDE HCL
  • PROCAINAMIDE HYDROCHLORIDE
  • N-(2-DIETHYLAMINOETHYL)-4-AMINOBENZAMIDE HYDROCHLORIDE
CAS:
614-39-1
MF:
C13H22ClN3O
MW:
271.79
EINECS:
210-381-7
Product Categories:
  • API
  • C8 to C20+
  • Amides
  • Bioactive Small Molecules
  • Building Blocks
  • Carbonyl Compounds
  • Cell Biology
  • Chemical Synthesis
  • Organic Building Blocks
  • P
  • PROCAN
  • Sodium channel
  • Benzene derivatives
Mol File:
614-39-1.mol
More
Less

Procainamide hydrochloride Chemical Properties

Melting point:
165-168 °C
Density 
1.2027 (rough estimate)
refractive index 
1.6330 (estimate)
storage temp. 
2-8°C
solubility 
H2O: soluble1g/10 mL, clear, greenish-yellow
form 
Powder
color 
White to slightly yellow
Water Solubility 
soluble
Sensitive 
Light Sensitive/Air Sensitive
Merck 
13,7845
BRN 
3729517
InChI
InChI=1S/C13H21N3O.ClH/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11;/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17);1H
InChIKey
ABTXGJFUQRCPNH-UHFFFAOYSA-N
SMILES
C1(=CC=C(N)C=C1)C(=O)NCCN(CC)CC.Cl
CAS DataBase Reference
614-39-1(CAS DataBase Reference)
EPA Substance Registry System
Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-, monohydrochloride (614-39-1)
More
Less

Safety Information

Hazard Codes 
Xn
Risk Statements 
22-36/37/38
Safety Statements 
26-36-37/39
WGK Germany 
3
RTECS 
CV2295000
HS Code 
29242990

MSDS

More
Less

Procainamide hydrochloride Usage And Synthesis

Chemical Properties

Procainamide hydrochloride is a white or light yellow crystalline powder with a melting point of 165–169 °C. It is soluble in water and ethanol, slightly soluble in chloroform, and very slightly soluble in ether or benzene. It is odorless and hygroscopic.

Uses

Procainamide hydrochloride (PAH) is suitable to investigate its binding behavior with human serum albumin and bovine serum albumin by fluorescence quenching study to understand the pharmacokinetic and pharmacodynamic mechanisms of PAH.

Uses

Class I antiarrhythmic

Definition

ChEBI: A hydrochloride which has procainamide as the amino component.

General Description

Procainamide hydrochloride,p-amino-N-[2-(diethylamino)ethyl]benzamidemonohydrochloride, procainamidium chloride (Pronestyl,Procan SR), has emerged as a major antiarrhythmic drug. Itwas developed in the course of research for compoundsstructurally similar to procaine, which had limited effectas an antiarrhythmic agent because of its central nervoussystem (CNS) side effects and short-lived action causedby rapid hydrolysis of its ester linkage by plasma esterases.Because of its amide structure, procainamide hydrochlorideis also more stable in water than is procaine. Aqueoussolutions of procainamide hydrochloride have a pH ofabout 5.5. A kinetic study of the acid-catalyzed hydrolysisof procainamide hydrochloride showed it to be unusuallystable to hydrolysis in the pH range 2 to 7, even at elevatedtemperatures.

Biochem/physiol Actions

Procainamide hydrochloride is a sodium channel blocker and Class IA anti-arrhythmic. It has also been shown to Inhibit DNA methyltransferase and modulate epigenetic regulation of gene expression.

Pharmacokinetics

Procainamide hydrochloride is metabolized through theaction of N-acetyltransferase. The product of enzymaticmetabolism of procainamide hydrochloride is N-acetylprocainamide(NAPA), which possesses only 25% of the activityof the parent compound. A study of the disposition ofprocainamide hydrochloride showed that 50% of the drugwas excreted unchanged in the urine, with 7% to 24% recoveredas NAPA. Unlike quinidine, procainamide hydrochlorideis bound only minimally to plasma proteins.Between 75% and 95% of the drug is absorbed from the gastrointestinaltract. Plasma levels appear 20 to 30 minutesafter administration and peak in about 1 hour. Procainamide hydrochloride appears to have all of theelectrophysiological effects of quinidine. It diminishesautomaticity, decreases conduction velocity, and increasesaction potential duration and, thereby, the refractory periodof myocardial tissue. Clinicians have favored the use of procainamidehydrochloride for ventricular tachycardias andquinidine for atrial arrhythmias, even though the two drugsare effective in either type of disorder.

Veterinary Drugs and Treatments

Procainamide potentially may be useful for the treatment of ventricular premature complexes (VPC’s), ventricular tachycardia, or supraventricular tachycardia associated with Wolff-Parkinson- White (WPW) syndrome with wide QRS complexes. Higher doses may be beneficial in the treatment of supraventricular tachycardias, although procainamide cannot be considered a first-line agent for this dysrhythmia.

Mode of action

Procainamide Hydrochloride is the hydrochloride salt form of procainamide, an amide derivative exhibiting class 1A antiarrhythmic property and analog of procaine. Procainamide hydrochloride reversibly binds to and blocks activated (open) voltage-gated sodium channels, thereby blocks the influx of sodium ions into the cell, which leads to an increase in threshold for excitation and inhibit depolarization during phase 0 of the action potential. In addition, the effective refractory period (ERP), action potential duration (APD), and ERP/APD ratios are increased, resulting in decreased impulse conduction velocity. The lasting action potential may also be due to blockage of outward K+ currents. The result is a decrease in automaticity, increase in refractory period and slowing of impulse conduction.

References

[1] KIRTHI BYADAGI. Investigation of binding behaviour of procainamide hydrochloride with human serum albumin using synchronous, 3D fluorescence and circular dichroism[J]. Journal of Pharmaceutical Analysis, 2017, 7 2: Pages 103-109. DOI:10.1016/j.jpha.2016.07.004.
[2] M. METI. Investigation of the interaction of the new antiarrhythmic drug procainamide hydrochloride with bovine serum albumin and the effect of some metal ions on the binding: a fluorescence quenching study[J]. Monatshefte für Chemie - Chemical Monthly, 2013, 163 1: 1253-1259. DOI:10.1007/s00706-013-0933-7.

Procainamide hydrochloride Preparation Products And Raw materials

Raw materials

Procainamide hydrochlorideSupplier

Chongqing Botao Biotechnology Co., LTD Gold
Tel
15223382610
Email
danny@chemdad.com
chemmole Gold
Tel
400-168-9330 15013243073
Email
597760450@qq.com
Shaanxi kelkai Pharmaceutical Technology Co., Ltd Gold
Tel
029-2148545164 17392779578
Email
2148545164@qq.com
Chongqing Xingcan Pharmaceutical Technology Co., Ltd. Gold
Tel
023-13650506873 19923294409
Email
xingcanyaoye@sina.com
J & K SCIENTIFIC LTD.
Tel
18210857532; 18210857532
Email
jkinfo@jkchemical.com